Expression of multidrug resistance proteins in invasive ductal carcinoma of the breast

Li,Weiquan; Song,Maomin

doi:10.3892/ol.2014.2435

Expression of multidrug resistance proteins in invasive ductal carcinoma of the breast

Authors:
- Weiquan Li
- Maomin Song
View Affiliations

Affiliations: Department of General Surgery, Beijing Tiantan Hospital, Capital University of Medical Sciences, Beijing 100050, P.R. China
Published online on: August 11, 2014 https://doi.org/10.3892/ol.2014.2435
Pages: 2103-2109

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemotherapy is commonly used for the treatment of breast cancer. However, the resistance to chemotherapeutic agents, often mediated by multidrug resistance (MDR) mechanisms, is a common occurrence. The present study examined the expression of several MDR‑related proteins (MRPs) in invasive ductal carcinoma (IDC) of the breast, and assessed their association with clinicopathological variables and their prognostic significance. In addition, immunohistochemistry was used to measure the expression of MRP, p‑glycoprotein (P‑gp), topoisomerase 2α (Topo2α), thymidylate synthase (TS) and glutathione‑S‑transferase π (GST‑π) in 156 resected IDCs of the breast. Pearson's χ2 test and Spearman's correlation coefficient were used to analyze the association between MDR protein expression and several clinicopathological variables. The association between each of the five MDR proteins was also examined. Furthermore, Kaplan‑Meier analysis and Cox regression modeling were used to assess overall survival. The expression of MRP, P‑gp, Topo2α, TS and GST‑π was detected in 20.5% (32/156), 25.0% (39/156), 84.0% (131/156), 41.7% (65/156) and 41.0% (64/156) of cases examined, respectively. No correlation was identified between MRP and Topo‑2α and the clinicopathological variables examined. By contrast, P‑gp (χ2=20.226; P<0.0001) and GST‑π (χ2=35.032; P<0.0001) were found to positively correlate with tumor grade. In addition, staining for TS was associated with axillary lymph node metastasis (χ2=42.281; P<0.0001). The expression levels of P‑gp and GST‑π were found to be significantly correlated (r= 0.319; P<0.0001). Furthermore, GST‑π expression was elevated in estrogen receptor‑negative breast cancer (χ2=17.407; P<0.0001). Tumor histological grade, in addition to TS and GST‑π expression, were significant predictors of a poor survival outcome. TS and GST‑π are consequently useful prognostic biomarkers in IDC, therefore, when establishing a personalized chemotherapeutic plan, the expression of MDR proteins must be considered.

View Figures

View References

1	Liu H, Liu Y and Zhang JT: A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpressionme-mediated palmitate overproduction. Mol Cancer Ther. 7:263–270
2	Cance WG, Carey LA, Calvo BF, et al: Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservating and predicits outstanding local control and survival. Ann Surg. 236:295–303. 2002.
3	Sachelarie I, Grossbard ML, Chadha M, et al: Primary systemic therapy of breast cancer. Oncologist. 11:574–589. 2006.
4	LaPensee EW and Ben-Jonathan N: Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy. Endocr Relat Cancer. 17:R91–R107. 2010.
5	Coley HM: Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 34:378–390. 2008.
6	Jacobs TW, Gown AM, Yaziji H, Barnes MJ and Schnitt SJ: Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 17:1983–1987. 1999.
7	Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002.
8	Sekine I and Saijo N: Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents. Ann Oncol. 12:1515–1525. 2001.
9	Orlowski S and Garrigos M: Multiple recognition of various amphiphilic molecules by the multidrug resistance P-glycoprotein: molecular mechanisms and pharmacological consequences coming from functional interactions between various drugs. Anticancer Res. 19:3109–3123. 1999.
10	Linn SC, Giaccone G, van Diest PJ, et al: Prognostic relevance of P-glycoprotein expression in breast cancer. Ann Oncol. 6:679–685. 1995.
11	Savas B, Bozcuk H, Özdo M, et al: Molecular and clinical parameters which determine the docetaxel response in metastatic breast cancer. J Clin Oncol. 22:97322004.
12	Cui SD, Liu ZZ, Liu H, Li LF, Yang H and Li WL: The relationship between 99mTc-MIBI scintimammography of breast cancer and multidrug-resistant proteins. Zhonghua Zhong Liu Za Zhi. 27:606–608. 2005.(In Chinese).
13	Chekhun VF, Zhylchuk VE, Lukyanova NY, Vorontsova AL and Kudryavets YI: Expression of drug resistance proteins in triple-receptor-negative tumors as the basis of individualized therapy of the breast cancer patients. Exp Oncol. 31:123–124. 2009.
14	Jakoby WB: The glutathione S-transferases: a group of multifunctional detoxification proteins. Adv Enzymol Relat Areas Mol Biol. 46:383–414. 1978.
15	Tew KD: Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 54:4313–4320. 1994.
16	Moscow JA, Townsend AJ, Goldsmith ME, et al: Isolation of the human anionic glutathione S-transferase cDNA and the relation of its gene expression to estrogen-receptor content in primary breast cancer. Proc Natl Acad Sci USA. 85:6518–6522. 1988.
17	Gilbert L, Elwood LJ, Merino M, et al: A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J Clin Oncol. 11:49–58. 1993.
18	Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D and Piccart MJ: Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol. 16:1723–1739. 2005.
19	Coon JS, Marcus E, Gupta-Burt S, et al: Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res. 8:1061–1067. 2002.
20	MacGrogan G, Rudolph P, Mascarel Id, et al: DNA topoisomerase IIalpha expression and the response to primary chemotherapy in breast cancer. Br J Cancer. 89:666–671. 2003.
21	Campiglio M, Somenzi G, Olgiati C, et al: Role of proliferation in HER2 status predicted response to doxorubicin. Int J Cancer. 105:568–573. 2003.
22	Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL and Ross JS: Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables. Mod Pathol. 13:542–547. 2000.
23	Rudolph P, Olsson H, Bonatz G, et al: Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol. 187:207–216. 1999.
24	Mukherjee A, Shehata M, Moseley P, Rakha E, Ellis I and Chan S: Topo2alpha protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer. Br J Cancer. 103:1794–1800. 2010.
25	Wang L, Jiang Z, Sui M, Shen J, Xu C and Fan W: The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study. BMC Cancer. 9:2262009.
26	Navalgund LG, Rossana C, Muench AJ and Johnson LF: Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. J Biol Chem. 255:7386–7390. 1980.
27	Carreras CW and Santi DV: The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem. 64:721–762. 1995.
28	Aschele C, Debernardis D, Casazza S, et al: Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol. 17:1760–1770. 1999.
29	Johnston PG, Fisher ER, Rockette HE, et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol. 12:2640–2647. 1994.
30	Suda Y, Kuwashima Y, Tanaka Y, Uchida K and Akazawa S: Immunohistochemical detection of thymidylate synthase in advanced gastric cancer: a prognostic indicator in patients undergoing gastrectomy followed by adjuvant chemotherapy with 5-fluoropyrimidines. Anticancer Res. 19:805–810. 1999.
31	Lee JH, Park JH, Jung Y, et al: Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol Cancer Ther. 5:3085–3095. 2006.
32	Gomez HL, Santillana SL, Vallejos CS, et al: A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res. 12:832–838. 2006.
33	Brandi M, Calascibetta A, Cabibi D, et al: Relationship between thymidylate synthase expression and p53 levels with the treatment of cyclophosphamide, methotrexate, 5-fluorouracil chemotherapy (CMF) versus docetaxel (TXT) in locally advanced carcinoma of the breast. J Clin Oncol. 24:105462006.